Delafloxacin

CHEMBL2105637 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
440.8 g/mol
LogP
2.7
Phase
4

A fluoroquinolone antibiotic with a unique anionic character that provides enhanced activity against Gram-positive bacteria including MRSA in addition to Gram-negative organisms, used for acute bacterial skin infections and community-acquired pneumonia. Its negative charge at physiological pH improves penetration into the acidic environment of infection sites.

Khối lượng phân tử

440,8000 g/mol

LogP

2,70

TPSA

120,00 Ų

Lipinski RO5

Đạt

Cơ chế tác dụng

Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Nc1nc(-n2cc(C(=O)O)c(=O)c3cc(F)c(N4CC(O)C4)c(Cl)c32)c(F)cc1F

InChI

InChI=1S/C18H12ClF3N4O4/c19-12-13-7(1-9(20)14(12)25-3-6(27)4-25)15(28)8(18(29)30)5-26(13)17-11(22)2-10(21)16(23)24-17/h1-2,5-6,27H,3-4H2,(H2,23,24)(H,29,30)

Molecular Formula

C18H12ClF3N4O4

HBD / HBA

3 / 11

Liên kết có thể quay

3

Nguyên tử nặng

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

A fluoroquinolone antibiotic with a unique anionic character that provides enhanced activity against Gram-positive bacteria including MRSA in addition to Gram-negative organisms, used for acute bacterial skin infections and community-acquired pneumonia. Its negative charge at physiological pH improves penetration into the acidic environment of infection sites.

Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.

Yes, Delafloxacin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2105637. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 487101. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.